AngioDynamics (NASDAQ:ANGO) Upgraded at Freedom Capital

Freedom Capital upgraded shares of AngioDynamics (NASDAQ:ANGO) to a strong-buy rating in a report issued on Monday morning,Zacks.com reports.

A number of other brokerages have also recently weighed in on ANGO. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, January 21st. Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a research report on Sunday, December 21st. Canaccord Genuity Group lowered their price target on AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Zacks Research cut AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, AngioDynamics has a consensus rating of “Moderate Buy” and an average target price of $18.67.

AngioDynamics Price Performance

Shares of NASDAQ:ANGO opened at $10.17 on Monday. The business’s fifty day moving average price is $10.83 and its two-hundred day moving average price is $11.53. AngioDynamics has a fifty-two week low of $8.36 and a fifty-two week high of $13.99. The stock has a market capitalization of $419.21 million, a price-to-earnings ratio of -13.56 and a beta of 0.43.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The firm had revenue of $78.42 million for the quarter, compared to analysts’ expectations of $76.77 million. Research analysts expect that AngioDynamics will post -0.37 EPS for the current fiscal year.

Institutional Trading of AngioDynamics

Several large investors have recently made changes to their positions in ANGO. State of Alaska Department of Revenue bought a new stake in shares of AngioDynamics during the third quarter worth $25,000. Farther Finance Advisors LLC grew its holdings in shares of AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 1,199 shares during the last quarter. Washington Trust Advisors Inc. bought a new stake in shares of AngioDynamics during the third quarter worth $27,000. Kemnay Advisory Services Inc. bought a new stake in shares of AngioDynamics during the fourth quarter worth $27,000. Finally, State of Wyoming bought a new stake in shares of AngioDynamics during the second quarter worth $31,000. Institutional investors own 89.43% of the company’s stock.

More AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Freedom Broker initiated coverage with a Buy recommendation, providing fresh buy-side attention that can lift demand for the shares. Freedom Broker initiates coverage of AngioDynamics (ANGO) with buy recommendation
• Positive Sentiment: Zacks upgraded ANGO to a Rank #2 (Buy), signaling growing optimism on earnings prospects and potentially drawing momentum investors. AngioDynamics (ANGO) Upgraded to Buy: Here’s Why
• Positive Sentiment: Freedom Capital (reported via Zacks reference) upgraded to “strong-buy,” adding to the cluster of bullish broker views that can support higher multiple re‑rating. Zacks.com
• Positive Sentiment: HC Wainwright raised several near‑term and FY2026/FY2027 EPS forecasts across multiple quarters (Q1/Q2/Q3/Q4 2027 and FY2026/FY2027), narrowing losses and showing improving profitability trends — this is a key fundamental driver behind the bullish sentiment. MarketBeat – AngioDynamics analyst estimate updates
• Negative Sentiment: Canaccord Genuity cut its price target to $16.00 — while still above the current share price, the downgrade in target could temper upside expectations for some investors. Canaccord Genuity Lowers AngioDynamics Price Target to $16.00

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.